NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Aug 18, 2021
Trial Information
Current as of July 12, 2025
Recruiting
Keywords
ClinConnect Summary
The NCCR AntiResist study is investigating how to fight against antibiotic-resistant bacteria, which can cause serious infections like urinary tract infections, pneumonia, and deep-seated infections. The trial is taking place at the University Hospital of Basel and focuses on four specific bacteria that are a major concern worldwide: E. coli, Klebsiella species, S. aureus, and P. aeruginosa. Researchers will analyze leftover patient samples to learn more about how these bacteria behave and how they resist treatment.
To participate, you must be between 65 and 74 years old and have a confirmed infection caused by one of the four bacteria mentioned. Healthy volunteers or patients without detectable bacteria may also be included as controls but will need to provide consent for their samples to be used. If you join the study, you can expect to contribute to important research that aims to improve treatment options for infections caused by antibiotic-resistant bacteria. Your participation could help lead to new strategies to combat these challenging infections, benefiting many patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Patients with confirmed (i) urinary tract infection, (ii) pneumonia (including patients after lung transplantation, cystic fibrosis) or (iii) deep-seated infection with focus pathogen:
- • E. coli
- • Klebsiella species
- • S. aureus
- • P. aeruginosa
- • Controls: no detectable bacteria in routine microbiology lab and no other infection site at inclusion of the sample and follow up for 10 days, signed general consent
- * Clinical controls without obtained samples, but with confirmed (i) urinary tract infection, (ii) pneumonia (including patients after lung transplantation, cystic fibrosis) or (iii) deep-seated infection with focus pathogen:
- • E. coli
- • Klebsiella species
- • S. aureus
- • P. aeruginosa
- Exclusion Criteria:
- • Patients who have refused research and reuse of their data/samples (e.g. general consent) or any other decline (e.g. Patientenverfügung).
- • other than one of the focus bacteria in routine microbiology lab
- • Age: \<18 years
- • Controls without signed general consent
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, , Switzerland
Patients applied
Trial Officials
Nina Khanna, Prof.
Principal Investigator
University Hospital Basel, Division of Infectiology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials